(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 11 December 2003 (11.12.2003)

PCT

(10) International Publication Number WO 03/101448 A1

(51) International Patent Classification⁷: 45/06, A61P 9/10

A61K 31/40,

(21) International Application Number: PCT/EP03/05762

2 June 2003 (02.06.2003)

(25) Filing Language:

English

(26) Publication Language:

(22) International Filing Date:

English

(30) Priority Data: 60/385,220

3 June 2002 (03.06.2002) US

- (71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): HOLMES, David, Grenville [CH/CH]; Holeeholzweg 75, CH-4102 Binningen (CH). HUGHES, Thomas, Edward [US/US]; 89 Wilson Road, Concord, MA 01742 (US).

- (74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.
- (84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THE USE OF SUBSTITUTED CYANOPYRROLIDINES AND COMBINATION PREPARATIONS CONTAINING THEM FOR TREATING HYPERLIPIDEMIA AND ASSOCIATED DISEASES

(57) Abstract: Disclosed are methods and compositions for the treatment of hyperlipidemia and conditions associated therewith, such as CHD, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, myocardial infarction (e.g. necrosis and apoptosis), dyslipidemia and post-prandial lipemia. The methods include administration of a therapeutically effective amount of a compound of formula (I), wherein R is substituted adamantyl; and N is 0 to 3; in free form or in acid addition salt form, and a pharmaceutically acceptable carrier.



A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/40 A61K45/06 A

A61P9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) $IPC \ 7 \ A61K$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		
Category •	Citation of document, with Indication, where appropriate, of the	ne relevant passages	Relevant to claim No.
х	WO 00 34241 A (NOVARTIS ERFIND GMBH; NOVARTIS AG (CH); VILLHA BE) 15 June 2000 (2000-06-15) cited in the application page 7, paragraph 2 page 8, paragraph 2 -page 9, per example 1 claims 1-9	UER EDWIN	1-17
X	US 6 011 155 A (VILLHAUER EDWI 4 January 2000 (2000-01-04) examples 47,49,53 claims 5,9,10	N BERNARD) -/	3
X Furti	her documents are listed in the continuation of box C.	Patent family members are listed i	n annex.
•	ategories of cited documents : ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international	"T" later document published after the inter or priority date and not in conflict with the clied to understand the principle or the invention "X" document of particular relevance; the clied cannot be considered novel or cannot.	he application but ory underlying the aimed invention be considered to
consider of filing of the citation other of the course of the citation of the	ent which may throw doubts on priority claim(s) or its cited to establish the publication date of another in or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but han the priority date claimed	'Y' document of particular relevance; the cl cannot be considered to involve an inv document is combined with one or mo- ments, such combination being obviou in the art.	aimed invention entive step when the re other such docu– s to a person skilled
consider con	ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another in or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but	'Y' document of particular relevance; the cl cannot be considered to involve an inv document is combined with one or mon ments, such combination being obviou in the art.	aimed invention entive step when the re other such docu- s to a person skilled
consider of the constant of the course of th	ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another n or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but han the priority date claimed	'Y' document of particular relevance; the cl cannot be considered to involve an inv document is combined with one or mon ments, such combination being obviou in the art. '&' document member of the same patent f	aimed invention entive step when the re other such docu- s to a person skilled amily



Internation Mo PCT/EP 03/05762

Category °	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
alegury	Onation of addition, with indication, where appropriate, of the televant passages	ACATOM TO CAME NO.
	US 6 166 063 A (VILLHAUER EDWIN BERNARD) 26 December 2000 (2000-12-26) cited in the application example 1 claims 1-9	3
· , X	WO 03 038123 A (NOVARTIS PHARMA GMBH; NOVARTIS AG (CH); LAVEDAN CHRISTIAN NICOLAS) 8 May 2003 (2003-05-08) page 23, paragraph 1 page 46, paragraph 3	1-3,5-7
4	EP 1 125 922 A (WELFIDE CORP) 22 August 2001 (2001-08-22) the whole document	1–17
A	EP 0 187 052 A (PANMEDICA SA) 9 July 1986 (1986-07-09) page 24, line 28 - line 35 claims 1-19	1-17
٠		





Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	emational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claims 1, 5-9 and 11-17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. X	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	see FURTHER INFORMATION sheet PCT/ISA/210
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the Invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest
	No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claim 9-17 relate to the treatment of a disease which actually is not well defined.

The use of the definition "lowering LDL, Lp(a) and/or VLDL levels in a mammal" in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. It is not fully possible to determine the disease for which protection might legitimately be sought. The lack of clarity is such as to render a meaningful search over the whole scope of the claims impossible.

Consequently, the search has been restricted to the real and defined disease states mentioned in claim 1 and 7, i.e. hyperlipidemia, atherosclerosis, angina pectoris, carotid artery disease, cerebral arteriosclerosis, xanthoma, CHD, ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudification, myocardial infarction, dyslipidemia and post-prandial lipemia.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0034241	A	15-06-2000	AU	759773 B	2 01-05-2003
	•	10 00 2000	ŬA	1658000 A	
			BR	9915985 A	
			CA	2350609 A	
			CN	1329593 T	
			CZ	20012028 A	
			WO	0034241 A	
			EP	1137635 A	
			HU	0104495 A	
			JP	2002531547 T	
			NO.	20012853 A	
			PL	348043 A	
			SK	7892001 A	
			TR	200101478 T	
			TW	509674 B	
			ÜS	6166063 A	
			ZA	200104581 A	22-05-2002
US 6011155	A	04-01-2000	US 	6124305 A	26-09-2000
US 6166063	Α	26-12-2000	ΑU	759773 B	2 01-05-2003
			AU	1658000 A	26-06-2000
			BR	9915985 A	
			CA	2350609 A	
			CN	1329593 T	
			CZ	20012028 A	
			WO	0034241 A	
			EP	1137635 A	
			ΗÜ	0104495 A	
			JP	2002531547 T	24-09-2002
			NO	20012853 A	
			PL	348043 A	
			SK	7892001 A	
			TR	200101478 T	
			TW	509674 B	11-11-2002
			ŽĀ	200104581 A	22-05-2002
 WO 03038123	 A	08-05-2003	 WO	03038123 A	
EP 1125922	Α	22-08-2001	AU	6367399 A	
			CA	2348879 A	
			EΡ	1125922 A	
			US	6468998 B	
			CN	1332726 T	
			WO	0026186 A	1 11-05-2000
EP 0187052	Α	09-07-1986	FR	2572399 A	
			ΑT	49957 T	
			AU	583543 B	2 04-05-1989
			AU	4884685 A	08-05-1986
			DE	3575715 D	
			EΡ	0187052 A	
			ES	8702888 A	
			JP	61109766 A	28-05-1986
			KR	9203837 B	
			US	4661512 A	28-04-1987